FDA’dan ilaç güvenliği bilgilendirmesi

FDA’dan ilaç güvenliği bilgilendirmesi (İng)

Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) – Should Not Be Used in Patients with Mechanical Prosthetic Heart Valves

December 19, 2012

Audience: Cardiology, Patients.

The U.S. Food and Drug Administration (FDA) is informing health care professionals and the public that the blood thinner (anticoagulant) Pradaxa (dabigatran etexilate mesylate) should not be used to prevent stroke or blood clots (major thromboembolic events) in patients with mechanical heart valves, also known as mechanical prosthetic heart valves.